Xiaomin Lu

407 total citations · 1 hit paper
16 papers, 307 citations indexed

About

Xiaomin Lu is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Xiaomin Lu has authored 16 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 13 papers in Hepatology and 7 papers in Surgery. Recurrent topics in Xiaomin Lu's work include Liver Disease Diagnosis and Treatment (12 papers), Liver Diseases and Immunity (11 papers) and Pediatric Hepatobiliary Diseases and Treatments (5 papers). Xiaomin Lu is often cited by papers focused on Liver Disease Diagnosis and Treatment (12 papers), Liver Diseases and Immunity (11 papers) and Pediatric Hepatobiliary Diseases and Treatments (5 papers). Xiaomin Lu collaborates with scholars based in United States, United Kingdom and Austria. Xiaomin Lu's co-authors include Robert P. Myers, Chuhan Chung, Christopher L. Bowlus, Andrew J. Muir, Michael Trauner, Kris V. Kowdley, G. Mani Subramanian, Charles Landis, Mitchell L. Shiffman and Andrew N. Billin and has published in prestigious journals such as Hepatology, Journal of Hepatology and European Respiratory Journal.

In The Last Decade

Xiaomin Lu

15 papers receiving 302 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

2019 205 citations Michael Trauner, Aliya Gulamhusein et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaomin Lu United States	6	225	210	141	118	54	16	307
Georgia Li United States	4	193 0.9×	214 1.0×	116 0.8×	98 0.8×	27 0.5×	4	290
Seung Kak Shin South Korea	11	156 0.7×	170 0.8×	60 0.4×	39 0.3×	28 0.5×	34	289
Eun Kyu Park South Korea	10	162 0.7×	139 0.7×	138 1.0×	107 0.9×	67 1.2×	21	308
Michaël Fernandez Belgium	6	269 1.2×	223 1.1×	207 1.5×	29 0.2×	149 2.8×	7	398
Stefan Gilg Sweden	12	293 1.3×	195 0.9×	196 1.4×	89 0.8×	51 0.9×	46	395
Bhupinder S. Anand United States	7	238 1.1×	272 1.3×	33 0.2×	32 0.3×	24 0.4×	11	350
Martina Milana Italy	9	173 0.8×	153 0.7×	99 0.7×	42 0.4×	23 0.4×	38	297
Petra Kloeters-Plachky Germany	11	211 0.9×	162 0.8×	219 1.6×	77 0.7×	165 3.1×	14	396
Enrico O. Souto United States	6	177 0.8×	146 0.7×	135 1.0×	34 0.3×	67 1.2×	12	305
Mahmood Tazari Canada	6	133 0.6×	114 0.5×	111 0.8×	39 0.3×	9 0.2×	6	250

Countries citing papers authored by Xiaomin Lu

Since Specialization

Citations

This map shows the geographic impact of Xiaomin Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaomin Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaomin Lu more than expected).

Fields of papers citing papers by Xiaomin Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaomin Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaomin Lu. The network helps show where Xiaomin Lu may publish in the future.

Co-authorship network of co-authors of Xiaomin Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaomin Lu. A scholar is included among the top collaborators of Xiaomin Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaomin Lu. Xiaomin Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Nathan, Steven D., Jie Gao, Ho Cheol Kim, et al.. (2025). Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 66(5). 2402565–2402565.

Newsome, Philip N., Naim Alkhouri, Rebecca Taub, et al.. (2025). P4 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis. A16–A17. 1 indexed citations

Alkhouri, Naim, Rebecca Taub, Xiaomin Lu, et al.. (2025). LBO-002 Treatment with resmetirom for up to two years led to improvement in liver stiffness, fibrosis biomarkers, fibrosis scores and portal hypertension risk in 122 patients with compensated MASH cirrhosis. Journal of Hepatology. 82. S9–S10. 1 indexed citations

Loomba, Rohit, Naim Alkhouri, Mazen Noureddin, et al.. (2024). TOP-264 Paired assessment of enhanced liver fibrosis (ELF) and fibrosis-4 (FIB-4) scores is associated with an elevated risk of liver-related clinical events in participants with advanced fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). Journal of Hepatology. 80. S505–S505. 1 indexed citations

Liang, Xiaolong, et al.. (2024). MicroRNA-145-5p Regulates the Epithelial-Mesenchymal Transition in Nasal Polyps by Targeting Smad3. Clinical and Experimental Otorhinolaryngology. 17(2). 122–136. 2 indexed citations

Levy, Cynthia, Stephen H. Caldwell, Parvez Mantry, et al.. (2024). Cilofexor in Patients With Compensated Cirrhosis Due to Primary Sclerosing Cholangitis: An Open-Label Phase 1B Study. Clinical and Translational Gastroenterology. 15(8). e00744–e00744. 1 indexed citations

Thorburn, Douglas, Diana Julie Leeming, William Barchuk, et al.. (2024). Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis. Hepatology Communications. 8(7). 5 indexed citations

Trauner, Michael, Chuhan Chung, Xiangyu Liu, et al.. (2023). PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis. BMC Gastroenterology. 23(1). 75–75. 14 indexed citations

Trauner, Michael, Cynthia Levy, Atsushi Tanaka, et al.. (2023). A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of cilofexor in patients with non-cirrhotic primary sclerosing cholangitis (PRIMIS). Journal of Hepatology. 78. S12–S13. 8 indexed citations

10.

Trauner, Michael, Christopher L. Bowlus, Aliya Gulamhusein, et al.. (2022). Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC. Clinical Gastroenterology and Hepatology. 21(6). 1552–1560.e2. 28 indexed citations

11.

Trivedi, Palak, Andrew J. Muir, Cynthia Levy, et al.. (2020). Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology. 19(6). 1248–1257. 34 indexed citations

12.

Trauner, Michael, Aliya Gulamhusein, Bilal Hameed, et al.. (2019). The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.. Hepatology. 3 indexed citations

13.

Bowlus, Christopher L., Mitchell L. Shiffman, Harry L.A. Janssen, et al.. (2019). PS-012-Validation of histologic and non-invasive measures of fibrosis as surrogate end points of disease progression in patients with primary sclerosing cholangitis. Journal of Hepatology. 70(1). e10–e11. 1 indexed citations

14.

Trauner, Michael, Aliya Gulamhusein, Bilal Hameed, et al.. (2019). The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 70(3). 788–801. 205 indexed citations breakdown →

15.

Eaton, John E., Konstantinos Lazaridis, Pietro Invernizzi, et al.. (2019). FRI-016-Validation of the PREsTo machine learning algorithm for the prediction of disease progression in patients with primary sclerosing cholangitis. Journal of Hepatology. 70(1). e390–e391. 2 indexed citations

16.

Trivedi, Palak, Andrew J. Muir, Cynthia Levy, et al.. (2019). PS-016-Prospective evaluation of serum alkaline phosphatase variability and prognostic utility in primary sclerosing cholangitis using controlled clinical trial data. Journal of Hepatology. 70(1). e12–e13. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact